Ashoka Buildcon JV wins ₹1,041 crore BMC flyover project
Ashoka Buildcon and Aakshya Infra win ₹1,041.44 crore BMC contract for Mumbai flyover connecting J.J. Bridge and Sitaram Selam Bridge.
Enforcement Directorate aims to end legacy FERA cases by early 2026
The criminal sections-loaded FERA of 1973 was replaced in June 2000 by the Foreign Exchange Management Act (FEMA) of 1999, a civil law
Godrej Properties sells over ₹2,600-crore homes in 1st year of operation in Hyderabad, looks to expand biz
Across all markets, Godrej Properties achieved a 13% growth in sales bookings to ₹15,587 crore in the first six months of this fiscal year from ₹13,835 crore in the year-ago period.
Ola Electric commences hyperdelivery for its 4680 Bharat Cell powered vehicles
Under hyperdelivery initiative, customers can complete their purchase online or at an Ola Electric Store and take home their fully registered vehicles on the same day
IndiGo: Turbulent skies
The airline, which commands a 65% share of India’s domestic aviation market, says operations are stabilising after days of chaos that saw hundreds of flight cancellations
We want BRIDGE to be the Davos for media: DG of UAE Media Office
Held by the private BRIDGE Alliance, but under the aegis of the Government of the UAE, the three-day summit brought together voices from journalism, cinema, music, technology and communications to deliberate on issues ranging from misinformation and trust deficits to the growing influence of artificial intelligence on global media ecosystems
Textile industry calls for removal of import duty on cotton
Income Tax department sends SMS/emails for bogus political donation claims
The Central Board of Direct Taxes (CBDT) alerts that a huge amount of bogus claims have been made on account of donations to Registered Unrecognised Political Parties (RUPPs) or Charitable Institutions and reduced their tax obligations
US Biosecure Act fuels China+1 opportunity for Indian CDMOs; Piramal Pharma sees long-term upside
Indian drug makers could gain from a gradual global supply chain realignment as US restrictions on China-linked biotech contracts take shape, with Piramal Pharma flagging early customer interest but cautioning that revenue gains are likely to materialise only over the medium term.